April 2, 2019
Pfizer Japan and Mochida Pharmaceutical have entered into a license agreement for the exclusive rights to develop and commercialize the US giant’s antidepressant treatment desvenlafaxine in Japan, they said on April 1. In Japan, desvenlafaxine, a selective serotonin and norepinephrine...read more